Skip to main content
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 2004 Aug 16;114(4):598. doi: 10.1172/JCI200420864E1

A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model

Rolf Postina, Anja Schroeder, Ilse Dewachter, Juergen Bohl, Ulrich Schmitt, Elzbieta Kojiro, Claudia Prinzen, Kristina Endres, Christoph Hiemke, Manfred Blessing, Pascaline Flamez, Antoine Dequenne, Emile Godaux, Fred van Leuven, Falk Fahrenholz
PMCID: PMC503762

Original citation: J. Clin. Invest. 113:1456–1464(2004). doi:10.1172/JCI200420864.

Citation for this Corrigendum: J. Clin. Invest. 114:142 (2004). doi:10.1172/JCI200420864E1.

During the preparation of this manuscript for publication, an error was introduced into the Results section, in the fourth sentence of the paragraph beginning with “The levels of the APP-derived soluble peptides Aβ40 and Aβ42 in brains of double-transgenic mice and APP[V717I] control animals at the age of 18 weeks were quantified by specific sandwich ELISAs.” The correct sentence appears below. We regret this error.

In line ADAM10-mo × APP[V717I], Aβ40 and Aβ42 were reduced by 49% and 20%, and in line ADAM10-hi × APP[V717I], by 39% and 29%, respectively.


Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES